It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pathogenic variants of the aconitase 2 gene (ACO2) are responsible for a broad clinical spectrum involving optic nerve degeneration, ranging from isolated optic neuropathy with recessive or dominant inheritance, to complex neurodegenerative syndromes with recessive transmission. We created the first public locus-specific database (LSDB) dedicated to ACO2 within the “Global Variome shared LOVD” using exclusively the Human Phenotype Ontology (HPO), a standard vocabulary for describing phenotypic abnormalities. All the variants and clinical cases listed in the literature were incorporated into the database, from which we produced a dataset. We followed a rational and comprehensive approach based on the HPO thesaurus, demonstrating that ACO2 patients should not be classified separately between isolated and syndromic cases. Our data highlight that certain syndromic patients do not have optic neuropathy and provide support for the classification of the recurrent pathogenic variants c.220C>G and c.336C>G as likely pathogenic. Overall, our data records demonstrate that the clinical spectrum of ACO2 should be considered as a continuum of symptoms and refines the classification of some common variants.
Measurement(s) | sequence_variant • Phenotypic variability |
Technology Type(s) | DNA sequencing • Ophthalmologist |
Factor Type(s) | sequence variant • phenotype |
Sample Characteristic - Organism | Homo sapiens |
Machine-accessible metadata file describing the reported data:
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Centre Hospitalier Universitaire d’Angers, Département d’Ophtalmologie, Angers, France (GRID:grid.411147.6) (ISNI:0000 0004 0472 0283)
2 Université d’Angers, Unité Mixte de Recherche MITOVASC, CNRS 6015/INSERM 1083, Angers, France (GRID:grid.7252.2) (ISNI:0000 0001 2248 3363)
3 Université d’Angers, Unité Mixte de Recherche MITOVASC, CNRS 6015/INSERM 1083, Angers, France (GRID:grid.7252.2) (ISNI:0000 0001 2248 3363); Centre Hospitalier Universitaire d’Angers, Département de Biochimie et Génétique, Angers, France (GRID:grid.411147.6) (ISNI:0000 0004 0472 0283)
4 Université d’Angers, Unité Mixte de Recherche MITOVASC, CNRS 6015/INSERM 1083, Angers, France (GRID:grid.7252.2) (ISNI:0000 0001 2248 3363); Mohammed First University, Genetics, and immuno-cell therapy Team, Oujda, Morocco (GRID:grid.7252.2)
5 Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS, Singapore (GRID:grid.272555.2) (ISNI:0000 0001 0706 4670)
6 Leiden University Medical Centre, Human Genetics and Clinical Genetics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)